Jundishapur Journal of Chronic Disease Care

Published by: Kowsar

Hepatitis C Virus Treatment with Sofosbuvir Plus Ribavirin Regimen in Khuzestan Province

Pezhman Alavinejad 1 , * , Eskandar Hajiani 1 , Seyed Jalal Hashemi 1 , Ali Akbar Shayesteh 1 , Kaveh Ebadi Borna 2 , Mohamad Amin Nasooti 3 and Said Reza Modares Mousavi 1
Authors Information
1 Alimentary Tract Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
2 GI Fellowship, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
3 Medical Faculty, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
Article information
  • Jundishapur Journal of Chronic Disease Care: October 31, 2018, 7 (4); e81105
  • Published Online: December 10, 2018
  • Article Type: Research Article
  • Received: June 22, 2018
  • Revised: October 14, 2018
  • Accepted: December 3, 2018
  • DOI: 10.5812/jjcdc.81105

To Cite: Alavinejad P, Hajiani E, Hashemi S J, Shayesteh A A, Ebadi Borna K, et al. Hepatitis C Virus Treatment with Sofosbuvir Plus Ribavirin Regimen in Khuzestan Province, Jundishapur J Chronic Dis Care. 2018 ; 7(4):e81105. doi: 10.5812/jjcdc.81105.

Abstract
Copyright © 2018, Jundishapur Journal of Chronic Disease Care. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Methods
3. Results
4. Discussion
Footnotes
References
  • 1. Ghany MG, Strader DB, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: An update. Hepatology. 2009;49(4):1335-74. doi: 10.1002/hep.22759. [PubMed: 19330875].
  • 2. European Association for Study of Liver. EASL recommendations on treatment of Hepatitis C 2015. J Hepatol. 2015;63(1):199-236. doi: 10.1016/j.jhep.2015.03.025. [PubMed: 25911336].
  • 3. Bourliere M, Bronowicki JP, de Ledinghen V, Hezode C, Zoulim F, Mathurin P, et al. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: A randomised, double-blind, phase 2 trial (SIRIUS). Lancet Infect Dis. 2015;15(4):397-404. doi: 10.1016/S1473-3099(15)70050-2. [PubMed: 25773757].
  • 4. Forns X, Charlton M, Denning J, McHutchison JG, Symonds WT, Brainard D, et al. sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation. Hepatology. 2015;61(5):1485-94. doi: 10.1002/hep.27681. [PubMed: 25557906].
  • 5. Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, et al. sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013;368(20):1867-77. doi: 10.1056/NEJMoa1214854. [PubMed: 23607593].
  • 6. Zeuzem S, Dusheiko GM, Salupere R, Mangia A, Flisiak R, Hyland RH, et al. sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med. 2014;370(21):1993-2001. doi: 10.1056/NEJMoa1316145. [PubMed: 24795201].
  • 7. Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Symonds WT, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med. 2013;368(1):34-44. doi: 10.1056/NEJMoa1208953. [PubMed: 23281974].
  • 8. Forns X, Gordon SC, Zuckerman E, Lawitz E, Calleja JL, Hofer H, et al. Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent. J Hepatol. 2015;63(3):564-72. doi: 10.1016/j.jhep.2015.04.009. [PubMed: 25895428].
  • 9. Sawinski D, Kaur N, Ajeti A, Trofe-Clark J, Lim M, Bleicher M, et al. Successful treatment of hepatitis C in renal transplant recipients with direct-acting antiviral agents. Am J Transplant. 2016;16(5):1588-95. doi: 10.1111/ajt.13620. [PubMed: 26604182].
  • 10. Asselah T, Boyer N, Saadoun D, Martinot-Peignoux M, Marcellin P. Direct-acting antivirals for the treatment of hepatitis C virus infection: Optimizing current IFN-free treatment and future perspectives. Liver Int. 2016;36 Suppl 1:47-57. doi: 10.1111/liv.13027. [PubMed: 26725897].
  • 11. Koff RS. Review article: The efficacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection. Aliment Pharmacol Ther. 2014;39(5):478-87. doi: 10.1111/apt.12601. [PubMed: 24387618].
  • 12. Lawitz E, Lalezari JP, Hassanein T, Kowdley KV, Poordad FF, Sheikh AM, et al. sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: A randomised, double-blind, phase 2 trial. Lancet Infect Dis. 2013;13(5):401-8. doi: 10.1016/S1473-3099(13)70033-1. [PubMed: 23499158].
  • 13. Lawitz E, Poordad F, Brainard DM, Hyland RH, An D, Dvory-Sobol H, et al. sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis. Hepatology. 2015;61(3):769-75. doi: 10.1002/hep.27567. [PubMed: 25322962]. [PubMed Central: PMC4365682].
  • 14. Lam AM, Espiritu C, Bansal S, Micolochick Steuer HM, Niu C, Zennou V, et al. Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus. Antimicrob Agents Chemother. 2012;56(6):3359-68. doi: 10.1128/AAC.00054-12. [PubMed: 22430955]. [PubMed Central: PMC3370800].
  • 15. Maasoumy B, Vermehren J, Welker MW, Bremer B, Perner D, Honer Zu Siederdissen C, et al. Clinical value of on-treatment HCV RNA levels during different sofosbuvir-based antiviral regimens. J Hepatol. 2016;65(3):473-82. doi: 10.1016/j.jhep.2016.04.006. [PubMed: 27085252].
  • 16. Foster GR, Pianko S, Brown A, Forton D, Nahass RG, George J, et al. Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection. Gastroenterology. 2015;149(6):1462-70. doi: 10.1053/j.gastro.2015.07.043. [PubMed: 26248087].
  • 17. Ruane PJ, Ain D, Stryker R, Meshrekey R, Soliman M, Wolfe PR, et al. sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry. J Hepatol. 2015;62(5):1040-6. doi: 10.1016/j.jhep.2014.10.044. [PubMed: 25450208].
  • 18. Charlton M, Gane E, Manns MP, Brown RS Jr, Curry MP, Kwo PY, et al. sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology. 2015;148(1):108-17. doi: 10.1053/j.gastro.2014.10.001. [PubMed: 25304641].
  • 19. Sulkowski MS, Rodriguez-Torres M, Lalezari JP, Fessel JW, Mounzer K, Shuhort MC, et al. All-oral therapy with sofosbuvir plus ribavirin for the treatment of Hcv Genotype 1, 2, and 3 infection in patients co-infected with Hiv (photon-1): 212. Hepatology. 2013;58:313A-4A.
  • 20. Osinusi A, Meissner EG, Lee YJ, Bon D, Heytens L, Nelson A, et al. sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: A randomized clinical trial. JAMA. 2013;310(8):804-11. doi: 10.1001/jama.2013.109309. [PubMed: 23982366]. [PubMed Central: PMC4254410].
  • 21. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, et al. sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368(20):1878-87. doi: 10.1056/NEJMoa1214853. [PubMed: 23607594].
  • 22. Wyles DL. Beyond telaprevir and boceprevir: Resistance and new agents for hepatitis C virus infection. Top Antivir Med. 2012;20(4):139-45. [PubMed: 23154254]. [PubMed Central: PMC6148907].
  • 23. Akhondi MM, Salman RH, Amirbigi MK, Azizi R. [Conventional versus pegylated interferons in treatment of hcv patients]. J Shahid Sadoughi Univ Med Sci Health Serv. 2012;20(1 (82)):49-57. Persian.
  • 24. Bafandeh Y, Saberi Firoozi M, Bagheri Lankarani K. [Evaluation of combination therapy with interferon and ribavirin in patients with chronic hepatitis C: A genotype based study]. J Mazandaran Univ Med Sci. 2007;17(57):9-16. Persian.
  • 25. Bourliere M, Wendt A, Fontaine H, Hezode C, Pol S, Bronowicki JP. How to optimize HCV therapy in genotype 1 patients with cirrhosis. Liver Int. 2013;33 Suppl 1:46-55. doi: 10.1111/liv.12067. [PubMed: 23286846].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments